Global Blood Therapeutics, Inc. - Common Stock (NQ:GBT)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, Oct 4, 2022 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Global Blood Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >

Pfizer, Global Blood Therapeutics In Advanced Talks For $5B Buyout Deal: Report ↗

August 05, 2022

Pfizer Inc (NYSE: PFE) is reportedly in advanced talks to buy Global Blood Therapeutics Inc (NASDAQ: GBT) for about $5 billion, bolster its portfolio and pipeline.

Via Benzinga

Coinbase, MercadoLibre And Some Other Big Stocks Recording Gains On Thursday ↗

August 05, 2022

U.S. stocks closed mixed on Thursday following the release of weekly jobless claims data. Here is the list of some big stocks moving higher in the previous session.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

August 04, 2022

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

August 04, 2022

Via Benzinga

Recap: Global Blood Therapeutics Q1 Earnings ↗

May 04, 2022

Global Blood Therapeutics (NASDAQ:GBT) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

Via Benzinga

Why NanoViricides Jumped Over 48%; Here Are 106 Biggest Movers From Yesterday ↗

August 05, 2022

Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) surged 109.2% to settle at $50.43 on Thursday after the company, and Amgen, announced an agreement under which Amgen will acquire the company for $52 per share...

Via Benzinga

Why ChemoCentryx Is Trading Higher By 110%, Here Are 95 Stocks Moving In Thursday's Mid-Day Session ↗

August 04, 2022

Gainers InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) shares jumped 178.5% to $12.45 after gaining over 12% on Wednesday.

Via Benzinga

Alibaba, MercadoLibre And Some Other Big Stocks Moving Higher In Today's Pre-Market Session ↗

August 04, 2022

Via Benzinga

Why Is Yellow Trading Higher By 33%: Here Are 48 Stocks Moving Premarket ↗

August 04, 2022

Gainers Missfresh Limited (NASDAQ: MF) shares rose 112.9% to $0.2450 in pre-market trading after dropping 7% on Wednesday.

Via Benzinga

Why Global Blood Therapeutics Stock Is Surging After Hours ↗

August 03, 2022

Global Blood Therapeutics Inc (NASDAQ: GBT) shares are soaring in Wednesday's after-hours session following a report suggesting the company is attracting takeover interest.

Via Benzinga

7 Small-Cap Growth Stocks With 1,000% Upside Potential ↗

July 31, 2022

Here're 7 small-cap growth stocks with 1,000% upside potential. ACLS, AXSM, GBT, GPRO, HCAT, SKLZ, and VERU can make great investments.

Via InvestorPlace

Recap Of Tuesday's Biotech Catalysts - End of The Day Summary ↗

July 26, 2022

Via Benzinga

Daily Biotech Pulse: EU Approval For AbbVie's Ulcerative Colitis Treatment, Angion Biomedica Evaluates Alternatives, Clinical Hold For Immuron's Bacterial Infection Candidate ↗

July 26, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Do You Have Biotech FOMO? Why Cogent, Arvinas And Others Are Flying ↗

July 06, 2022

Biotech stocks continued going gangbusters Wednesday. Here's why, experts say.

Via Investor's Business Daily

Global Blood Therapeutic Stock Sees Relative Strength Rating Rise To 91 ↗

July 05, 2022

Global Blood Therapeutic stock saw a positive improvement to its Relative Strength Rating on Tuesday, rising from 85 to 91.

Via Investor's Business Daily

Looking Into Global Blood Therapeutics's Return On Capital Employed ↗

June 28, 2022

According to Benzinga Pro data, during Q1, Global Blood Therapeutics (NASDAQ:GBT) posted sales of $55.16 million. Earnings were up 7.03%, but Global Blood Therapeutics still reported an overall loss of...

Via Benzinga

How Global Blood Therapeutics Thinks It Can Take On Crispr's Gene Editing ↗

June 10, 2022

The company is using a different approach to tackle the blood disease.

Via Investor's Business Daily

7 No-Brainer Biotech Stocks to Add to Your Buy List ↗

June 09, 2022

With the broader markets grumbling, investors should consider biotech stocks to buy for their permanently relevant profile.

Via InvestorPlace

Global Blood Therapeutics Earnings Perspective: Return On Capital Employed ↗

May 20, 2022

According to data from Benzinga Pro, during Q1, Global Blood Therapeutics's (NASDAQ:GBT) reported sales totaled $55.16 million. Despite a 7.03% increase in earnings, the company posted a loss of $81.42...

Via Benzinga

Looking Into Global Blood Therapeutics's Return On Capital Employed ↗

April 26, 2022

Global Blood Therapeutics (NASDAQ:GBT) brought in sales totaling $56.10 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 23.37%, resulting in a loss of $87.58...

Via Benzinga

What 4 Analyst Ratings Have To Say About Global Blood Therapeutics ↗

February 28, 2022

Global Blood Therapeutics (NASDAQ:GBT) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish...

Via Benzinga

Recap: Global Blood Therapeutics Q4 Earnings ↗

February 23, 2022

Global Blood Therapeutics (NASDAQ:GBT) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:05 PM. Here's what investors need to know about the announcement...

Via Benzinga

The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development ↗

February 23, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase...

Via Benzinga

The Daily Biotech Pulse: Avenue Tumbles On Negative Adcom Verdict, Moderna's Expanded Deal With Rovi, Gilead Takes Equity Stake In Hookipa ↗

February 16, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hookipa Gets $15M Upfront Payment And Equity Investment From Gilead Following...

Via Benzinga

The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow ↗

February 20, 2022

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front...

Via Benzinga

Stock Wars: Axsome Therapeutics Vs. Global Blood Therapeutics ↗

February 02, 2022

Benzinga’s weekly Stock Wars matches up two leaders in a major industry sector with the goal of determining which company is the better investment.

Via Benzinga

The Journey To Rewrite Human DNA Is About To Get Wild, Thanks To Pfizer, Bayer, Intellia And Other CRISPR stocks ↗

January 13, 2022

Big Pharma is paying attention to CRISPR stocks. Could that alight shares this year?

Via Investor's Business Daily

FDA Expands Use Of Global Blood' Sickle Cell Treatment To Kids Aged 4-12 Years ↗

December 20, 2021

The FDA has granted accelerated approval to Global Blood Therapeutics Inc's (NASDAQ: GBT) supplemental application seeking approval for Oxbryta (voxelotor...

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

December 17, 2021

Gainers GBS (NASDAQ:GBS

Via Benzinga

Global Blood Raises $300M Via Convertible Debt Offering ↗

December 15, 2021

Global Blood Therapeutics Inc (NASDAQ: GBT) priced $300 million Convertible Senior Notes due 2028 in a private offering. The offering size was increased from...

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.